Pharma
We are pleased to invite you to the 3rd Annual Antibody Summit: Biscpecifics & Multispecifics scheduled for May 15 - 16, 2019 in Vienna, Austria.
Read moreWe are pleased to invite you to the 3rd Annual Antibody Summit: Biscpecifics & Multispecifics scheduled for May 15 - 16, 2019 in Vienna, Austria.
This premier B2B event provides the appropriate platform to engage and discuss ideas with your fellow peers, while facilitating a professional atmosphere and environment for good company representation and development. The Summit will shed light on the progress in discovery, development and therapeutics of novel protein therapeutics, and the latest breakthrough engineering next-generation antibody formats. It is an honour and privilege to invite you to participate in this Summit.
We look forward to welcoming you in Vienna in May!
Chief Executives, Vice Presidents, Directors, Heads, Leaders and Managers specializing in:
About Speaker
About Speaker
About Speaker
About Speaker
About Speaker
About Speaker
About Speaker
About Speaker
About Speaker
About Speaker
About Speaker
Max Woisetschlaeäger holds a PhD in pharmaceutical sciences at the University of Vienna and is an appointed associate professor for molecular biology. From 1988-90 he was a post-doctoral fellow at the Dana-Farber Cancer Institute, Harvard Medical School in Boston. Afterwards, he joined Novartis Pharma AG, where he was responsible for the identification of novel drug targets and the identification and development of potential clinical drug candidates up to clinical PhI in the fields of oncology, auto-immunity and allergy. In 2008 he joined F-star, where he was responsible for the biophysical, biochemical and biological characterisation of antigen binding immunoglobulin Fc fragments and bi-specific antibodies. In 2012, he re-joined Novartis as a director of biologics in the field of inflammation, auto-immunity and transplantation.
Siddharth Sukumaran is a drug development scientist at Genentech. He received his doctoral and postdoctoral training in pharmacokinetics and pharmacodynamics, and modeling and simulation from University at Buffalo. His technical expertise is in preclinical, translational and clinical PKPD, mechanistic mathematical modeling and pharmacometrics. His drug development experience spans multiple therapeutic areas including oncology, immuno-oncology, fibrotic, autoimmune and inflammatory diseases. He has extensive experience with monoclonal antibodies, ADCs, cytokine therapy, fusion proteins and bispecific/multimeric antibody formats. He serves as pharmacology sub-team leader, leading cross-functional teams supporting IND/CTA-enabling preclinical studies, FIH studies, clinical development and regulatory filings. He has contributed to several regulatory filings, been an author or co-inventor of more than 30 research articles, reviews, book chapters and patents, and has been an invited speaker to numerous conferences.
In his role as senior director of CMC operations, Christian Cimander is leading the early stage CMC development team at Genmab. Together with his team, Christian is responsible for managing the CMC development of Genmab’s antibody programs from DNA to FIH supply.
Christian has almost 20 years of experience within the biotech industry. During his 11 years at Genmab, he has worked within CMC development for many of Genmab’s program covering very early stage through multiple BLA programs as e.g. Genmab’s daratumumab (Darzalex) program. Christian is a biochemical engineer by training and holds a PhD in biotechnology. Christian lives together with his wife and two children in Malmö, Sweden.
Ercole Rao received his PhD in molecular biology from the University of Heidelberg. He has 18 years of industrial experience, 14 of those spent in antibody discovery and research and development. Ercole heads a group for protein engineering at Sanofi with a focus on multispecific antibody technologies. Since 2009, Ercole’s team has moved three bispecific antibodies into clinical development
Dr. Thomas Huber’s current role is technology leader and co-project team leader for bispecific modalities at NIBR biologics center in Basel. In 2012-13, he was appointed project team leader at respiratory disease in Horsham, UK. He joined Novartis Basel in 2007 and has established several technology platforms in the field of therapeutic antibody and protein engineering. Thomas received his PhD in the group of prof. Andreas Plückthun at the department of biochemistry of the University of Zürich.
Andy Goodearl has extensive experience in biopharmaceutical industry in the discovery, research and early development of biologics drugs at Abbott/Abbvie since 2003 and for seven years at Millennium Pharmaceuticals prior to that. Currently, he’s the senior director of biologics discovery group focussed on late stage research and early development of biologics drugs for immunology, oncology and neuroscience indications. Responsibilities have encompassed candidate generation and optimisation of monoclonal antibodies for immunology, oncology and neuroscience projects, development of characterised manufacturing cell lines, expression technology development, production and characterisation of research reagent proteins and assay tools, hybridoma technologies, clinical assay discovery and in vitro pharmacology (primary and safety pharmacology). Currently, he’s a leader of a cross functional initiative focussed on next generation biologics acting locally in disease tissues through local delivery, engineered retention characteristics and/or disease epitope targeting mechanisms.
Andy trained as a protein biochemist at the University of Birmingham UK followed by postdoctoral training at Ludwig Institute for Cancer Research, London, and at the neuroscience department at Harvard Medical School. Scientific accomplishments documented in over 20 peer-reviewed publications and 15-plus patents.
Dr. Benjamin Smith is a scientist at Biogen in biologics drug discovery, CNS delivery, where the focus is to develop innovative biotherapeutic technologies to fill unmet need for patients with neurodegenerative disorders. Trained as a biophysicist and biochemist, Benjamin is active in the field of blood-brain barrier research with focus on discovery and engineering of antibodies that transport across the BBB.
Benjamin received PhD in physics from McGill University, with specialisation in cellular mechanics. As a postdoctoral scientist, he trained in membrane biophysics at the University of British Columbia and in single-molecule biochemistry at Brandeis University.
Elke Glasmacher works at Roche pRED, where since 2017 she has been heading a department in large molecule research, responsible for the lead generation process and scientific developments. She worked at Grünenthal in Aachen, studied biology in Cologne and moved for her main courses in biochemistry to Boston and then the Max Planck Institute of Biochemistry in Planegg, Germany. She then switched to immunology for her PhD thesis and described a mechanism that prevents autoreactive T cells and lupus. She moved in 2010 to Genentech as a postdoctoral fellow and discovered a genomic regulatory element that drives differentiation programs of immune cells. In 2013 she established an independent investigator laboratory at the Helmholtz Center Munich, where she continued to work on molecular factors driving immune cell fate and activation, with which she continues to be associated.
Laura von Schantz is director of antibody engineering at Alligator Bioscience and works with projects in discovery and all the way to the clinic, ensuring the manufacturability of novel immuno-oncology drug candidates. Laura believes that companies in the competitive field of immuno-oncology must invest in establishing advantageous technologies and processes to be able to generate in short-time compounds with novel function and high developability. Laura has established a platform (including a novel bispecific format) at Alligator that allows for fast generation of novel drug candidates with excellent properties in respect to function, manufacturability and stability. Laura is trained in protein chemistry, antibody engineering and crystallography as well as project management and corporate strategy. Laura holds a PhD in immunotechnology from the University of Lund.
Weon-Kyoo You received his PhD in biochemistry at Yonsei University in 2004. Then, he worked as a postdoctoral fellow at UC San Francisco, and as a researcher at Sanford-Burnham Prebys Medical Discovery Institute from 2004-12. He successfully performed several research projects and published many peer-reviewed papers in the field of tumour-induced angiogenesis and tumour microenvironments. After he came back to Korea, he worked until March 2016 at the Hanwha Chemical R&D Center as a principal research scientist to discover and develop a novel bispecific antibody. Currently, he is working as the R&D head at a startup biotech company, ABL Bio, Inc., and leading new antibody-based drug development projects, especially focussed on the clinical development of the bispecific antibody targeting dual angiogenesis targets, VEGF & DLL4.
Dr. Mariangela Figini is currently working as group leader at Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy. Mariangela received his PhD in biology from the University of Pavia, Italy, and completed his master’s in microbiology and virology from the University of Milano, Italy. From 1991-93, she worked at the MRC Cambridge, UK, under the supervision of Sir Greg Winter (Nobel Prize for chemistry 2018). Mariangela has authored more than 60 publications in various internationally-ranked journals and books. Research interest: she is mainly focussed on antibody engineering, in particular the use of antibody to redirect nanoparticles, toxic agents and CAR-T for tumour therapy.
Thank you for your interest!